Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
GlobeNewswire
· Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in..